Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579152 | 1.00 | SLC10A2 (0.86) | SLC10A2 | |
| SCHEMBL2584937 | 1.00 | SLC10A2 (0.86) | SLC10A2 | |
| SCHEMBL2591806 | 0.97 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL2590146 | 0.95 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL2592663 | 0.95 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL2589727 | 0.93 | SLC10A2 (0.74) | SLC10A2 | |
| Linerixibat SCHEMBL2579144 | 0.92 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL29429786 | 0.92 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL2586025 | 0.92 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL2584943 | 0.92 | SLC10A2 (1.00) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599602-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-04-14 | — | — | US | disclosed |
| US-12576079-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-03-17 | — | — | US | disclosed |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240391885-A1 | FORMS OF LINERIXIBAT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2024-11-28 | — | — | US | disclosed |
| EP-4464376-A2 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | Mirum Pharmaceuticals, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4424363-A2 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | Mirum Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11918578-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4245367-A2 | METHODS FOR TREATING CHOLESTASIS | Mirum Pharmaceuticals, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20210113585-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20200375989-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2020167958-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167964-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | MIRUM PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167981-A1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-12599602-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | SLC10A2 2/4885 |
| US-20240391885-A1 | FORMS OF LINERIXIBAT | PYGL, DCXR, CYP2C9 | SLC10A2 44/4885 |
| US-20210113585-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20130029938-A1 | Chemical Compounds | CYP11B1, GOT2, CYP11B2 | SLC10A2 171/4885 |
| US-12576079-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | SLC10A2 2/4885 |
| US-11918578-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20200375989-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.